IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients

Frontiers in Medicine

article

Savino Sciascia¹  Irene Cecchi¹  Massimo Radin¹  Elena Rubini¹  Ana Suárez²  Dario Roccatello¹  Javier Rodríguez-Carrio² 

[1] Center of Research of Immuno-pathology and Rare Diseases, Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin;Department of Functional Biology, Faculty of Medicine, University of Oviedo;Instituto de Investigación Sanitaria del Principado de Asturias (ISPA);Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, Hospital Universitario Central de Asturias

关键词: antiphospholipid syndrome;    thrombosis;    anti-HDL;    autoimmunity;    autoantibodies;   

DOI  :  10.3389/fmed.2019.00211

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Introduction: Recurrent thrombotic events are a hallmark of Antiphospholipid Syndrome (APS). However, biomarkers to identify if a patient with antiphospholipid antibodies (aPL) is at higher risk to develop an arterial or a venous event are lacking. Recently, the pathogenic role of anti-high-density lipoproteins antibodies (anti-HDL) in the occurrence of cardiovascular disease (CVD) in autoimmunity has emerged. The aim of the present study was to evaluate the presence of IgG anti-HDL antibodies in a cohort of thrombotic APS patients and to investigate their association with clinical outcomes. Methods: Serum levels of IgG anti-HDL antibodies, total IgG, and complete aPL profile were assessed in 60 APS patients and 80 healthy donors (HDs) by immunoassays. Results: Higher levels of IgG anti-HDL were found in APS patients compared to HDs ( p < 0.001), even after correcting for total IgG levels ( p < 0.001). No associations with treatments or traditional cardiovascular risk factors, except for smoking habit ( p < 0.0001), were found. Patients who experienced at least one arterial event ( n = 30) had significantly higher levels of anti-HDL antibodies when compared to patients with venous thrombosis ( n = 30, p = 0.046), this difference being stronger when adjusting for total IgG ( p = 0.007). Additionally, patients tested positive for antiphosphatidylserine/prothrombin (IgG/IgM) antibodies had significantly higher levels of anti-HDL antibodies ( p = 0.045). Conclusions: Increased levels of IgG anti-HDL antibodies can be found in APS, mainly in patients with arterial thrombosis, independently of aPL antibodies and traditional risk factors. These findings point to a role of anti-HDL antibodies in APS and support their use as a potential biomarker for arterial thrombotic events.

【 授权许可】

CC BY